Pharmaceutical composition for treatment of abnormal energy metabolism and application thereof

An energy metabolism and composition technology, which is applied in the fields of drug combination, metabolic diseases, and medical preparations containing active ingredients, etc., can solve the problems of fatty acid and glucose metabolism imbalance, no drug energy metabolism, mitochondrial dysfunction, etc. Rehabilitation, treatment of mitochondrial dysfunction, the effect of optimizing productivity

Active Publication Date: 2011-05-18
CHANGZHOU HI TECH DISTRICT MULTIPLE DIMENSION IND TECH INST
View PDF2 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, fatty acid oxidation consumes more oxygen than glucose oxidation, and it can only play a role in the case of sufficient oxygen supply, and it is inappropriate to promote fatty acid oxidation one-sidedly under the condition of ischemia and hypoxia
[0008] In addition to the above two types of drugs, no better drugs have been found clinically for the treatment of abnormal energy metabolism, imbalance of fatty acid and glucose metabolism, and mitochondrial dysfunction
And above-mentioned drugs all have certain defect clinically

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treatment of abnormal energy metabolism and application thereof
  • Pharmaceutical composition for treatment of abnormal energy metabolism and application thereof
  • Pharmaceutical composition for treatment of abnormal energy metabolism and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0048] Example 1 The curative effect of trimetazidine and levocarnitine pharmaceutical composition on acute myocardial ischemia-reperfusion injury in rats, the curative effect on abnormal energy metabolism caused by myocardial ischemia, and the effect on the comprehensive balance of fatty acid and glucose metabolism , and efficacy against mitochondrial dysfunction.

[0049] During acute ischemia and reperfusion of the myocardium, due to insufficient oxygen, the energy supply of the myocardium changes from aerobic oxidation of fatty acids to glycolysis to provide energy. Therefore, a large amount of lactic acid produced by glycolysis leads to accumulation of acid products, A series of pathological changes such as aggravated peroxidation and damage to myocardial ultrastructure.

[0050] In order to observe the prevention and treatment effects of trimetazidine, levocarnitine and different ratios on acute myocardial ischemia-reperfusion injury, abnormal energy metabolism, and mito...

Embodiment 2

[0092] Example 2 Efficacy of Levocarnitine and Trimetazidine Composition in Treating Metabolic Syndrome and Abnormal Energy Metabolism

[0093] 2.1 Modeling method:

[0094] Animals: ordinary male Wistar rats, body weight 200±20g; after feeding with ordinary feed for 1 week, a) each model group was given high-sugar, high-fat, and high-salt feed (basic feed 58%, lard oil 8%, sucrose 22% , egg yolk 10%, salt 2%) to detect modeling indexes after 8 weeks. b) Normal control group: fed with common feed (containing 0.5% salt) for 8 weeks. All animals had free access to food and water

[0095] 2.2 Test drugs and grouping

[0096] 1) Drugs: Levocarnitine and trimetazidine hydrochloride were provided by Changzhou Sanwei Industrial Research Institute.

[0097] Solvent: normal saline. The test drug was prepared with normal saline to make an equal volume solution of corresponding concentration before use.

[0098] 2) Dose setting and experimental grouping

[0099] After the equivale...

Embodiment 3

[0129] Example 3 Efficacy of Levocarnitine and Trimetazidine Composition in Treating Abnormal Energy Metabolism of Liver Cancer

[0130] 3.1 Experimental method and dose setting

[0131] BALB / c mice, male. Weight 20-22g. 15 mice were randomly selected from each batch of 36 mice as the healthy group.

[0132] The remaining groups were subcutaneously injected with HepA cell suspension in the right forelimb, each 0.2mL (5x10 / ml) to prepare liver cancer samples.

[0133] Body tumor model. After the equivalent doses of trimetazidine and levocarnitine were calculated based on clinical human doses, each

[0134] There are 2 dosage groups, 4 groups including solvent group and control group. They are:

[0135] Trimetazidine (TMZ) group: solvent control group, TMZ 48mg / kg administration group, intraperitoneal injection.

[0136] L-carnitine (L-C) group: solvent control group, L-C 340mg / kg administration group, intragastric administration.

[0137] Trimetazidine + levocarnitine d...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
Login to view more

Abstract

The invention relates to a pharmaceutical composition for the treatment of abnormal energy metabolism, which is the pharmaceutical composition containing a) a medicine for promoting fatty acid oxidation or derivatives thereof and b) a medicine for promoting glucose oxidation or pharmaceutical salts thereof. The pharmaceutical composition can comprehensively balance the metabolisms of fatty acid and glucose, optimize the productivity of fatty acid and glucose, reduce the jeopardy of abnormal aggregation of acidic metabolites, including free fatty acid or lactic acid and the like on organism, treat mitochondrial dysfunction, improve the defect that trimetazidine and the like are likely to create the accumulation of free fatty acid owing to the suppression on the fatty acid oxidation, and can be used for the auxiliary treatment for a plurality of diseases featured by imbalanced energy metabolism, such as acute and chronic ischemia, traumas, serious infection, diabetes, tumors, etc.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating abnormal energy metabolism, which is used for regulating the imbalance of glucose and fatty acid metabolism and mitochondrial dysfunction. technical background [0002] In the life activities of animals, in addition to the exchange of oxygen and carbon dioxide, the decomposition and synthesis of glucose, fatty acids and proteins are also required, and the conversion of energy storage and consumption is required to meet the needs of life activities. Protein is an important component of the body's cells, and there is usually no redundant storage. Therefore, under normal circumstances, it is necessary to save protein consumption as much as possible, and the energy supply is mainly based on the oxidation of glucose and fatty acids. Usually, sugar oxidation accounts for about 50-70% of the total energy supply of the human body. Fat is the main energy storage method of the body, which can rea...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/495A61P1/00A61P1/08A61P1/16A61P3/00A61P3/10A61P5/00A61P7/08A61P9/00A61P9/10A61P9/12A61P11/00A61P13/12A61P15/00A61P17/00A61P19/00A61P21/00A61P21/04A61P25/00A61P25/06A61P39/02A61K31/205
CPCA61K31/495A61K31/205A61P1/00A61P1/02A61P1/04A61P1/08A61P1/12A61P1/16A61P1/18A61P3/00A61P3/10A61P5/00A61P7/08A61P9/00A61P9/10A61P9/12A61P11/00A61P13/12A61P15/00A61P17/00A61P19/00A61P21/00A61P21/04A61P25/00A61P25/06A61P25/14A61P25/28A61P31/00A61P35/00A61P39/02A61P43/00Y02A50/30A61K2300/00
Inventor 顾书华杜娟
Owner CHANGZHOU HI TECH DISTRICT MULTIPLE DIMENSION IND TECH INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap